WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 206573

CAS#: 3458-22-8

Description: Yoshi-864 is an alkylsulfonate DNA crosslinker with potential anticancer activity. Yoshi-864 alkylates and crosslinks DNA, thereby inhibiting DNA replication. Yoshi-864 evaluated in clinical trials in 1980s. No survival advantage was seen.

Price and Availability


Ask price

Ask price

Ask price

Yoshi-864 is not in stock, but may be available through custom synthesis. Minimum 1 gram order is requested. Current shipping out time is about 2 months after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 206573
Name: Yoshi-864
CAS#: 3458-22-8
Chemical Formula: C8H20ClNO6S2
Exact Mass:
Molecular Weight: 325.819
Elemental Analysis: C, 29.49; H, 6.19; Cl, 10.88; N, 4.30; O, 29.46; S, 19.68

Synonym: Yoshi-864; Yoshi 864; Yoshi864; NSC102627; NSC-102627; NSC 102627

IUPAC/Chemical Name: azanediylbis(propane-3,1-diyl) dimethanesulfonate hydrochloride


InChi Code: InChI=1S/C8H19NO6S2.ClH/c1-16(10,11)14-7-3-5-9-6-4-8-15-17(2,12)13;/h9H,3-8H2,1-2H3;1H


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Douglass HO Jr, MacIntyre JM, Kaufman J, Von Hoff D, Engstrom PF, Klaassen D. Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine. Cancer Treat Rep. 1985 May;69(5):543-5. PubMed PMID: 2988774.

2: Slavik M, Muss H, Blessing JA. Phase II clinical study of Yoshi 864 in squamous cell carcinoma of the uterine cervix. Cancer Treat Rep. 1983 Feb;67(2):195-6. PubMed PMID: 6297730.

3: Altman SJ, Stephens RL, Bonnet JD. Yoshi 864 plus medroxyprogesterone acetate in adenocarcinoma of the kidney: A Southwest Oncology Group Study. Cancer Treat Rep. 1982 Sep;66(9):1781-2. PubMed PMID: 6288240.

4: Slavik M, Muss H, Blessing JA, Delgado G. Phase II clinical study of Yoshi 864 in epithelial ovarian carcinoma: A Gynecologic Oncology Group Study. Cancer Treat Rep. 1982 Sep;66(9):1775-7. PubMed PMID: 6288239.

5: Meyn RE, Meistrich ML, White RA. Cycle-dependent anticancer drug cytotoxicity in mammalian cells synchronized by centrifugal elutriation. J Natl Cancer Inst. 1980 May;64(5):1215-9. PubMed PMID: 6154171.

6: Altman SJ, Metter GE, Nealon TF, Weiss AJ, Ramirez G, Madden RE, Fletcher WS, Strawitz JG, Multhauf PM. Yoshi 864 (1-propanol, 3,3'-iminodi-, dimethanesulfonate [ester], hydrochloride): a phase II study in solid tumors. Cancer Treat Rep. 1978 Mar;62(3):389-95. PubMed PMID: 206359.

7: Glae GR, Atkins LM, Meischen SJ, Smith AB, Walker EM Jr. Combination chemotherapy of L1210 leukemia with platinum compounds and cyclophosphamide plus other selected antineoplastic agents. J Natl Cancer Inst. 1976 Dec;57(6):1363-6. PubMed PMID: 187805.

8: Drewinko B, Barlogie B. Survival and cycle-progression delay of cultured human lymphoma cells treated with 1-propanol, 3,3'-iminodi-, dimethanesulfonate (ester), hydrochloride (Yoshi 864). Cancer Treat Rep. 1976 Nov;60(11):1637-45. PubMed PMID: 191191.

9: Gale GR, Smith AB, Atkins LM. Comparative effects of Yoshi-864 and busulfan on certain transplantable murine tumors. Proc Soc Exp Biol Med. 1975 May;149(1):98-101. PubMed PMID: 1170570.

10: Dowell KE, Armstrong DM, Aust JB, Cruz AB Jr. Systemic chemotherapy of advanced head and neck malignancies. Cancer. 1975 Apr;35(4):1116-20. PubMed PMID: 1116105.

11: Altman SJ, Fletcher WS, Andrews NC, Wilson WL, Pischer T. Yoshi 864 (NSC 102627) 1-propanol, 3, 3'-iminodi-dimethanesulfonate (ester) hydrochloride: a phase 1 study. Cancer. 1975 Apr;35(4):1145-7. PubMed PMID: 163676.

12: Hirano M, Miura M, Kakizawa H, Morita A, Uetani T, Ohno R, Kawashima K, Nishiwaki H, Yamada K. Treatment of chronic myelogenous leukemia with 3,3'-iminodi-1-propanol, dimethanesulfonate (ester), p-toluenesulfonate (NSC-140117) given orally. Cancer Chemother Rep. 1972 Jun;56(3):335-8. PubMed PMID: 19051492.